drugset / Trial / NCT01868243

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

NCT01868243

Phase 2/3 Terminated 27 enrolled Hospital Ana Nery
RandomizedParallel-groupOpen-labelTreatment

Summary

DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus. There are no formal primary or secondary clinical efficacy or safety outcomes because it is a pilot study.

Timeline

Start
2013-08
Primary completion
2014-09
Completion
2014-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran Unknown 110 mg
Comparator Warfarin Small molecule

Indications

No indication recorded.